NOS3 and metabolic syndrome: When healthy ECs are exposed in vitro to EVs derived from individuals with metabolic syndrome, there is a detrimental reduction in nitric oxide (NO) production via the inhibition of endothelial nitric oxide synthase (eNOS) activity.